Telemis, a leader in PACS, digital pathology, and healthcare Business Intelligence, concluded its 2023-2024 fiscal year with positive growth.
Louvain-la-Neuve, (Belgium), 03 September 2024
Telemis, a leader in PACS, digital pathology, and healthcare Business Intelligence, concluded its 2023-2024 fiscal year with positive growth.
The company reported a turnover of €11,964,467 and achieved a profit of €1,435,254, consolidating its twenty-second consecutive year of profitability.
Throughout 2023-2024, Telemis experienced significant advancements in its various solutions.
Several new healthcare facilities opted to implement Telemis PACS/MACS solutions, including the Réseau d'Imagerie Sud Francilien RISF (Évry-Courcouronnes, Draveil, Lieusaint, Villeneuve-Saint-Georges, Corbeil-Essonnes), the Groupe Hospitalier Sélestat-Obernai and the Centre Hospitalier Haute Gironde Blaye.
As a top 3 player in medical imaging software in France, Telemis has also been involved in the French “SEGUR de la Santé” initiative.
Numerous exciting discussions have taken place this year with contacts from the DNS (Délégation au Numérique en Santé) and the ANS (Agence du Numérique en Santé), professional unions and various manufacturers.
The TM-Microscopy digital pathology solution has experienced substantial growth in recent purchase orders, particularly due to new clients in Belgium (AZ Delta in Roeselare, CHwapi in Tournai, Labo Pathologie PA² ZAS in Antwerp), in France (the Cancer Centers of Caen, Lille, and Rouen), and a first reference in the South of Italy (Istituto Nazionale Tumori IRCCS Fondazione G. Pascale - Napoli) .
The outcomes of recent public tenders highlight Telemis digital pathology solution as the most advanced currently available on the market.
Over 20 healthcare sites are now using Intuitus-powered cockpits to manage their daily activities effectively. The solution provides hospital managers with customised data-driven cockpits to optimise operations and improve healthcare outcomes. Initially focused on imaging services and operating rooms, this year has marked a significant expansion into laboratory and financial analysis.
Throughout the year, Telemis participated in various international congresses held in Belgium, France, Germany, Italy, Luxembourg, Switzerland, and the United States.
Additionally, different user groups were organised to gather feedback and shape the roadmap for future releases.
Stephane Ketelaer, CEO of the Telemis Group, conveyed his satisfaction with this year's results by stating, "After many years of investment on all products, the Digital Pathology and Business Intelligence are now showing signs of future significant growth. We owe this result to the work of the whole Telemis team!"